Silver Book Fact

Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients receiving a high-dose lost <15 letters of acuity–compared with 55.6% in the combined low-dose/sham group.  The high-dose group had a 0.6 mean letter gain while the low-dose/sham group had a mean 9.7 letter loss.

Zhang K, Hopkins J, Heier J, Birch D, et al. Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration. PNAS. 2011; 108(15). http://www.pnas.org/content/early/2011/03/24/1018987108

Reference

Title
Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration
Publication
PNAS
Publication Date
2011
Authors
Zhang K, Hopkins J, Heier J, Birch D, et al
Volume & Issue
Volume 108, Issue 15
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.  
  • It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.  
  • Multifoca electroretinogram (mFERG) measures show abnormal function of the retina early in–and even prior to–diabetic retinopathy onset and could enhance monitoring of the early stages of disease progression in individuals.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.